top of page
iPharmaCenter
ipharmacenter Consulting services
ipharmacenter
Consulting services
ipharmacenter
Consulting services
ipharmacenter
Consulting services
Home
Pharma
US FDA Approvals
North America
China Drug Approvals
Japan Drug Approvals | Healthcare
India Drug Approvals
APAC - Drug Approvals
LACAM
Europe
Canada Drug Healthcare News
Brazil - Drug approvals
EMA News
APAC
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
NICE Assessment Outcomes
G-BA Assessment Outcomes
APAC - Healthcare News
Lacam Healthcare News
Healthcare Policies
Conferences
All News
For sponsored articles, link insertions, and advertisements, please write to
info@ipharmacenter.com
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
May witnessed the approval of Pfizer’s Talzenna, Nyprax’s Tukysa, Drug Houses’ Ajovy in Singapore
ipharmaservices
Jun 4, 2020
Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients
ipharmaservices
Jun 3, 2020
bottom of page
